Streamex STEX Q1 2026 Earnings Miss by Significant Key Takeaways IMF Raises UK Growth Forecast Endorses Reevess Fiscal Strategy Amid Bond Market Jitters Pop Culture CPOP Stock Down 156 Support Test at 030 20260515 Japans Stealth Bull Market Pathways for US Investors to Participate Goldman Sachs Maintains Bullish Gold Outlook Amid Rising Central Bank Demand Consumers Spend More in April Despite Elevated Gas Prices Latest Data Shows Elon Musk Loses OpenAI Lawsuit Yet Legal Battles Likely to Continue The AI Stock Landscape Shifting Analyst Focus Beyond the Usual Suspects Kontron AG Issues Voting Rights Announcement Under Austrian BrseG Genpact CEO Suggests AI May Reduce IT Workload and Slow Hiring in India ANET Q1 2026 Earnings EPS Beats Estimates by Nearly 6 Stock Climbs BW Q1 2026 Earnings Wide EPS Miss Weighs on Investor Sentiment MANH Q1 2026 Earnings Earnings Beat Driven by Strong Cloud Momentum EDIT Q1 2026 Earnings NarrowerthanExpected Loss Drives Stock Higher BTCS Q1 2026 Earnings EPS Misses Estimates as DevelopmentStage Company Faces Headwinds PSBD Q1 2026 Earnings Significant EPS Miss Driven by Unrealized Losses Lattice Semiconductor Holds Steady Near Key Support Amid Sector Volatility Cue Biopharma CUE Shows Modest Gain as Biotech Sector Watches Key Levels RCI Hospitality Holdings RICK Holds Steady Near Support Assessing the Move AMC Entertainment Climbs 245 as Meme Stock Momentum Faces Resistance at 163 Calamos Strategic Total Return CSQ Holds Near Resistance as Modest Gains Signal Cautious Optimism SpaceX Delays Starship V3 Test Flight Rescheduled for Friday Amid MultiBillion Dollar Development CareDx Q1 2026 Earnings Robust Profit Beat Drives Optimism Western Automakers Export ChinaMade Vehicles to Home Markets Amid Overcapacity OPCH Q1 2026 Earnings EPS Beat Fails to Lift Stock Revenue Picture Unclear Indian Equities Remain Under Foreign Selling Pressure Amid Outperformance of US Markets Corn Futures Decline at Midday Tuesday Amid Weather and Demand Concerns TVTX Q1 2026 Earnings EPS Misses Estimates as Clinical Costs Weigh on Results Stock Surges 78 Phio Pharmaceuticals PHIO Edges Higher Testing Key Resistance at 117